adistem - where it fits in the puzzle, page-8

Rud,

MLA have been working very hard on this transaction for over a year. They have announced this only after considerable due diligence when they are confident of getting the support they need.

They key point to remember is that it's being pitched at US investors where the appetite and support for stem cell technology companies is much stronger than domestic investors. The depreciation of the Australian dollar over the last two months can only help too.

Historical profits may be modest, however everyone has to start somewhere. The US investors will be more looking to the future and if they like what they see they'll invest. My own belief is that significant profits are not far away.

This stock flies beneath the radar and continues to be underrated. Announcing US institutions amongst the top 10 shareholders when the deal is done will hopefully be the spark that is needed.